

Pere Gin s

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9411031/publications.pdf>

Version: 2024-02-01

390
papers

50,789
citations

952

115
h-index

1676

214
g-index

421
all docs

421
docs citations

421
times ranked

18377
citing authors

#	ARTICLE	IF	CITATIONS
1	Renal Replacement Therapy for Acute Kidney Injury in Severe Alcohol-Associated Hepatitis as a Bridge to Transplant or Recovery. Digestive Diseases and Sciences, 2022, 67, 697-707.	2.3	7
2	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology, 2022, 75, 219-228.	7.3	107
3	Ductular reaction promotes intrahepatic angiogenesis through Slit2â€“Roundabout 1 signaling. Hepatology, 2022, 75, 353-368.	7.3	20
4	Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis. Journal of Hepatology, 2022, 76, 107-114.	3.7	21
5	Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis. Gut, 2022, 71, 148-155.	12.1	98
6	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 2276-2286.e6.	4.4	42
7	The EASLâ€“Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet, The, 2022, 399, 61-116.	13.7	257
8	Improving Outcome Prediction in Alcohol-Associated Hepatitis: Blood Urea Nitrogen and Albumin Help. Mayo Clinic Proceedings, 2022, 97, 436-438.	3.0	2
9	Molecular characterization of chronic liver disease dynamics: From liver fibrosis to acute-on-chronic liver failure. JHEP Reports, 2022, 4, 100482.	4.9	14
10	Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life. PLoS ONE, 2022, 17, e0265153.	2.5	18
11	Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. Hepatology Communications, 2022, 6, 1100-1112.	4.3	5
12	Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. Clinical Gastroenterology and Hepatology, 2022, 20, 2567-2576.e6.	4.4	80
13	Patterns of kidney dysfunction in acuteâ€“chronic liver failure: Relationship with kidney and patientsâ€™ outcome. Hepatology Communications, 2022, 6, 2121-2131.	4.3	8
14	Long-term albumin treatment in patients with cirrhosis and ascites. Journal of Hepatology, 2022, 76, 1306-1317.	3.7	16
15	EASL International Recognition Award Recipient 2022: Prof. Patrick S. Kamath. Journal of Hepatology, 2022, , .	3.7	0
16	Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis. Hepatology, 2021, 73, 571-585.	7.3	56
17	Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acuteâ€“chronic liver failure and acute decompensation. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 240-248.	2.8	11
18	Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis. Gastroenterology, 2021, 160, 206-218.e13.	1.3	89

#	ARTICLE	IF	CITATIONS
19	Programmed Death Ligand 1 Is Overexpressed in Liver Macrophages in Chronic Liver Diseases, and Its Blockade Improves the Antibacterial Activity Against Infections. <i>Hepatology</i> , 2021, 74, 296-311.	7.3	21
20	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	3.7	149
21	Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. <i>Journal of Hepatology</i> , 2021, 74, 200-219.	3.7	16
22	SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 156-158.	8.1	49
23	Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: A population-based study. <i>Liver International</i> , 2021, 41, 1556-1564.	3.9	16
24	Profiling circulating microRNAs in patients with cirrhosis and acute-on-chronic liver failure. <i>JHEP Reports</i> , 2021, 3, 100233.	4.9	14
25	Monitoring Renal Function and Therapy of Hepatorenal Syndrome Patients with Cirrhosis. <i>Clinics in Liver Disease</i> , 2021, 25, 441-460.	2.1	2
26	Reply. <i>Gastroenterology</i> , 2021, 160, 2206.	1.3	0
27	Reply to: "Acute-on-chronic liver failure in East-Asia: an underestimated issue with limited data". <i>Gut</i> , 2021, , gutjnl-2021-324926.	12.1	0
28	Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2021, 74, 1014-1048.	7.3	311
29	Hyperkalemia influences the outcome of patients with cirrhosis with acute decompensation (AD) and acute-on-chronic liver failure (ACLF). <i>Digestive and Liver Disease</i> , 2021, 53, 738-745.	0.9	5
30	Robert W Schrier, an influential observer from outside Hepatology (1936-2021). <i>Journal of Hepatology</i> , 2021, 74, 1281-1282.	3.7	0
31	The Use of Rifaximin in Patients With Cirrhosis. <i>Hepatology</i> , 2021, 74, 1660-1673.	7.3	67
32	The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. <i>Journal of Hepatology</i> , 2021, 75, S118-S134.	3.7	30
33	A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement. <i>Journal of Hepatology</i> , 2021, 75, 275-283.	3.7	23
34	Liver cirrhosis. <i>Lancet</i> , The, 2021, 398, 1359-1376.	13.7	515
35	Sequential changes in urinary biomarker levels in patients with cirrhosis and severe hepatorenal syndrome. <i>Liver International</i> , 2021, 41, 2729-2732.	3.9	6
36	...A double blind, randomised, placebo-controlled study to assess safety and tolerability of oral enterosorbent Carbalive (Yaq-001) in cirrhotic patients. , 2021, , .		5

#	ARTICLE	IF	CITATIONS
37	Editorial: microRNAs for the diagnosis of fatty liver disease in the population“are we inching closer towards the target?. Alimentary Pharmacology and Therapeutics, 2021, 53, 557-558.	3.7	1
38	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2020, 5, 31-41.	8.1	75
39	Lack of evidence for a continuum between hepatorenal syndrome“and acute tubular necrosis. Journal of Hepatology, 2020, 72, 581-582.	3.7	5
40	Are We Ready to Evaluate Adrenal Function in Patients With Decompensated Cirrhosis and Acute-on-Chronic Liver Failure?. Clinical Gastroenterology and Hepatology, 2020, 18, 1040-1042.	4.4	1
41	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. Journal of Hepatology, 2020, 72, 688-701.	3.7	223
42	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	3.7	282
43	Hepatic lipocalin 2 promotes liver fibrosis and portal hypertension. Scientific Reports, 2020, 10, 15558.	3.3	30
44	Hospital-Acquired Versus Community-Acquired Acute Kidney Injury in Patients With Cirrhosis: A Prospective Study. American Journal of Gastroenterology, 2020, 115, 1505-1512.	0.4	12
45	Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ, The, 2020, 370, m2687.	6.0	116
46	Psychological Burden of Hepatic Encephalopathy on Patients and Caregivers. Clinical and Translational Gastroenterology, 2020, 11, e00159.	2.5	32
47	Changing epidemiology and outcomes of acute kidney injury in hospitalized patients with cirrhosis “ a US population-based study. Journal of Hepatology, 2020, 73, 1092-1099.	3.7	43
48	Albumin in decompensated cirrhosis: new concepts and perspectives. Gut, 2020, 69, 1127-1138.	12.1	190
49	Reply to: “Transition of AKI to CKD in cirrhosis “ effect of baseline eGFR and unanswered questions”, Journal of Hepatology, 2020, 73, 738-739.	3.7	0
50	Clinical Application of Kidney Biomarkers in Cirrhosis. American Journal of Kidney Diseases, 2020, 76, 710-719.	1.9	55
51	Chronic Kidney Disease in Cirrhosis: Emerging Complication With Negative Impact in the Liver Transplant Setting. Liver Transplantation, 2020, 26, 483-484.	2.4	2
52	Nursing Care of Patients With Cirrhosis: The LiverHope Nursing Project. Hepatology, 2020, 71, 1106-1116.	7.3	22
53	Development of chronic kidney disease after acute kidney injury in patients with cirrhosis is common and impairs clinical outcomes. Journal of Hepatology, 2020, 72, 1132-1139.	3.7	43
54	Statins: Old drugs as new therapy for liver diseases?. Journal of Hepatology, 2019, 70, 194-202.	3.7	108

#	ARTICLE	IF	CITATIONS
55	Recomendaciones para la detección, diagnóstico y seguimiento de los pacientes con enfermedad por hígado graso no alcohólico en atención primaria y hospitalaria. Medicina Clínica, 2019, 153, 169-177.	0.6	18
56	Editorial: evaluating cirrhosis progression—lessons from the heart. Alimentary Pharmacology and Therapeutics, 2019, 50, 709-710.	3.7	1
57	Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. Journal of Hepatology, 2019, 71, 1141-1151.	3.7	104
58	Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. Medicina Clínica (English Edition), 2019, 153, 169-177.	0.2	7
59	Reply to: "Midodrine and albumin in decompensated cirrhosis: Down but not out". Journal of Hepatology, 2019, 70, 812.	3.7	0
60	Metabolomics Discloses a New Non-invasive Method for the Diagnosis and Prognosis of Patients with Alcoholic Hepatitis. Annals of Hepatology, 2019, 18, 144-154.	1.5	11
61	Hypervolemic Hyponatremia (Liver). Frontiers of Hormone Research, 2019, 52, 104-112.	1.0	7
62	Improvement of hyponatremia in cirrhosis is associated with improved complex information processing. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1999-2003.	2.8	11
63	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. Frontiers in Immunology, 2019, 10, 476.	4.8	134
64	Neutrophil Gelatinase-Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study. Hepatology, 2019, 70, 319-333.	7.3	114
65	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. Gastroenterology, 2019, 156, 1368-1380.e10.	1.3	296
66	Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. Journal of Hepatology, 2019, 70, 639-647.	3.7	101
67	Ductular Reaction Cells Display an Inflammatory Profile and Recruit Neutrophils in Alcoholic Hepatitis. Hepatology, 2019, 69, 2180-2195.	7.3	52
68	Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival. Liver International, 2019, 39, 1246-1255.	3.9	64
69	Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. Clinical Gastroenterology and Hepatology, 2019, 17, 54-64.e1.	4.4	59
70	New Strategies for the Management of Decompensated Cirrhosis: Long-Term Albumin Administration for Everyone?. Hepatology, 2019, 69, 2289-2291.	7.3	2
71	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. Journal of Hepatology, 2019, 70, 398-411.	3.7	225
72	Orchestration of Tryptophan-Kynurenine Pathway, Acute Decompensation, and Acute-on-Chronic Liver Failure in Cirrhosis. Hepatology, 2019, 69, 1686-1701.	7.3	80

#	ARTICLE	IF	CITATIONS
73	Serum sodium as a risk factor for hepatic encephalopathy in patients with cirrhosis and ascites. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 914-920.	2.8	16
74	EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 406-460.	3.7	1,762
75	High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1138-1145.e5.	4.4	180
76	Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1792-1800.e3.	4.4	127
77	More Than Meets the Eye in Using Interleukin 6 as a Marker of Inflammation and Prognostic Factor for Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 630-632.	4.4	0
78	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1495-1502.	4.4	83
79	Cell death markers in patients with cirrhosis and acute decompensation. <i>Hepatology</i> , 2018, 67, 989-1002.	7.3	76
80	Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. <i>Gut</i> , 2018, 67, 1870-1880.	12.1	375
81	Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). <i>Liver Transplantation</i> , 2018, 24, 369-379.	2.4	47
82	Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study. <i>PLoS ONE</i> , 2018, 13, e0200656.	2.5	21
83	Hepatorenal syndrome. <i>Nature Reviews Disease Primers</i> , 2018, 4, 23.	30.5	172
84	Hepatorenal syndrome in the era of acute kidney injury. <i>Liver International</i> , 2018, 38, 1891-1901.	3.9	42
85	Transient elastography for alcoholic liver disease: a step forward. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 589-591.	8.1	6
86	Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. <i>Journal of Hepatology</i> , 2018, 69, 1250-1259.	3.7	152
87	Metabolomics Discloses a New Non-invasive Method for the Diagnosis and Prognosis of Patients with Alcoholic Hepatitis. <i>Annals of Hepatology</i> , 2018, 17, 0-10.	1.5	0
88	A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis. <i>Hepatology</i> , 2017, 66, 555-563.	7.3	91
89	Terlipressin for hepatorenal syndrome: ready for prime time. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 75-76.	8.1	3
90	Acute-on-chronic liver failure: an update. <i>Gut</i> , 2017, 66, 541-553.	12.1	472

#	ARTICLE	IF	CITATIONS
91	Pentraxin α 3 modulates lipopolysaccharide-induced inflammatory response and attenuates liver injury. Hepatology, 2017, 66, 953-968.	7.3	39
92	Short article. European Journal of Gastroenterology and Hepatology, 2017, 29, 535-538.	1.6	0
93	Effects of alfa α pump α , α system on kidney and circulatory function in patients with cirrhosis and refractory ascites. Liver Transplantation, 2017, 23, 583-593.	2.4	37
94	Impact of Acute-on-Chronic Liver Failure (ACLF) on response to treatment with terlipressin and albumin in patients with type 1 hepatorenal syndrome. Digestive and Liver Disease, 2017, 49, e54.	0.9	3
95	Screening studies of transient elastography and FibroTest in the general population α “ Authors' reply. The Lancet Gastroenterology and Hepatology, 2017, 2, 246-247.	8.1	0
96	Juan Rod α “s α ”In Memoriam. Gastroenterology, 2017, 152, 1249-1250.	1.3	0
97	Urine Interleukin 18 and Lipocalin 2 Are Biomarkers of Acute Tubular Necrosis in Patients With Cirrhosis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2017, 15, 1003-1013.e3.	4.4	67
98	Reply to: α “Are we still searching for the fifth element of MELD? Journal of Hepatology, 2017, 66, 247-248.	3.7	0
99	Liver injury and glatiramer acetate, an uncommon association: case report and literature review. Therapeutic Advances in Neurological Disorders, 2017, 10, 367-372.	3.5	9
100	Pro: Acute α “n α “chronic liver failure. Liver Transplantation, 2017, 23, 1318-1324.	2.4	3
101	Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: Prediction and impact on long α “term survival. Hepatology, 2017, 66, 1842-1853.	7.3	119
102	Adipocyte Fatty-Acid Binding Protein is Overexpressed in Cirrhosis and Correlates with Clinical Outcomes. Scientific Reports, 2017, 7, 1829.	3.3	30
103	Polymorphisms in the IL α “1 gene cluster influence systemic inflammation in patients at risk for acute α “n α “chronic liver failure. Hepatology, 2017, 65, 202-216.	7.3	39
104	Clinical course and short α “term mortality of cirrhotic patients with infections other than spontaneous bacterial peritonitis. Liver International, 2017, 37, 385-395.	3.9	39
105	Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acute-on-Chronic Liver Failure. Clinical Gastroenterology and Hepatology, 2017, 15, 438-445.e5.	4.4	125
106	Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience. American Journal of Medicine, 2017, 130, 372-375.	1.5	31
107	Copeptin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival. Critical Care, 2017, 21, 321.	5.8	19
108	Urine Monocyte Chemoattractant Protein-1 Is an Independent Predictive Factor of Hospital Readmission and Survival in Cirrhosis. PLoS ONE, 2016, 11, e0157371.	2.5	20

#	ARTICLE	IF	CITATIONS
109	Response to nosocomial spontaneous bacterial peritonitis: discussing a specific infection treatment algorithm. <i>Liver International</i> , 2016, 36, 1075-1076.	3.9	0
110	Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. <i>Gut</i> , 2016, 65, 1535-1545.	12.1	103
111	LPS-TLR4 Pathway Mediates Ductular Cell Expansion in Alcoholic Hepatitis. <i>Scientific Reports</i> , 2016, 6, 35610.	3.3	25
112	Screening for liver fibrosis in the general population: a call for action. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 256-260.	8.1	131
113	Acute-on-Chronic Liver Failure: The Role of Precipitating Illness. <i>Seminars in Liver Disease</i> , 2016, 36, 117-122.	3.6	22
114	Management of Hepatorenal Syndrome in the Era of Acute-on-Chronic Liver Failure: Terlipressin and Beyond. <i>Gastroenterology</i> , 2016, 150, 1525-1527.	1.3	12
115	Targeting the renin-angiotensin system in liver fibrosis. <i>Hepatology International</i> , 2016, 10, 730-732.	4.2	4
116	Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. <i>Hepatology</i> , 2016, 64, 1249-1264.	7.3	550
117	Management of uninfected and infected ascites in cirrhosis. <i>Liver International</i> , 2016, 36, 109-115.	3.9	43
118	Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. <i>Journal of Hepatology</i> , 2016, 65, 914-920.	3.7	35
119	Acute-on-chronic liver failure in cirrhosis. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16041.	30.5	320
120	Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis. <i>Scientific Reports</i> , 2016, 6, 32341.	3.3	101
121	Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis B.. <i>Scientific Reports</i> , 2016, 6, 25487.	3.3	125
122	The TLR10 polymorphism rs4129009 is associated to poor 28-day survival in patients with cirrhosis and acute on chronic liver failure precipitated by bacterial infection. <i>Digestive and Liver Disease</i> , 2016, 48, e16.	0.9	0
123	The Management of Hyponatremia in Cirrhosis: Should it Be Pharmacologic?. <i>Current Hepatology Reports</i> , 2016, 15, 53-59.	0.9	0
124	Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. <i>Journal of Hepatology</i> , 2016, 65, 57-65.	3.7	112
125	Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. <i>Journal of Hepatology</i> , 2016, 64, 717-735.	3.7	243
126	Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2016, 64, 574-582.	3.7	196

#	ARTICLE	IF	CITATIONS
127	Pathogenesis of Hepatorenal Syndrome: Implications for Therapy. American Journal of Kidney Diseases, 2016, 67, 318-328.	1.9	74
128	Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats. Hepatology, 2016, 63, 207-216.	7.3	18
129	Kinase analysis in alcoholic hepatitis identifies p90RSK as a potential mediator of liver fibrogenesis. Gut, 2016, 65, 840-851.	12.1	14
130	Integrative miRNA and Gene Expression Profiling Analysis of Human Quiescent Hepatic Stellate Cells. Scientific Reports, 2015, 5, 11549.	3.3	79
131	Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes. Liver Transplantation, 2015, 21, 1347-1354.	2.4	48
132	Assessment of acute kidney injury at hospital admission in cirrhosis: estimating baseline serum creatinine is not the answer. Liver International, 2015, 35, 2079-2081.	3.9	4
133	Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology, 2015, 62, 243-252.	7.3	493
134	Analysis of a Urinary Biomarker Panel for Clinical Outcomes Assessment in Cirrhosis. PLoS ONE, 2015, 10, e0128145.	2.5	97
135	Chemokine Receptor Ccr6 Deficiency Alters Hepatic Inflammatory Cell Recruitment and Promotes Liver Inflammation and Fibrosis. PLoS ONE, 2015, 10, e0145147.	2.5	19
136	Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology, 2015, 62, 762-772.	7.3	230
137	Preface. Digestive Diseases, 2015, 33, 1-1.	1.9	0
138	Reply to: "A cut-off serum creatinine value of 1.5 mg/dl for AKI" To be or not to be? Journal of Hepatology, 2015, 62, 743-744.	3.7	2
139	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut, 2015, 64, 531-537.	12.1	405
140	Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. Journal of Hepatology, 2015, 62, 968-974.	3.7	571
141	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. Journal of Hepatology, 2015, 62, 831-840.	3.7	289
142	Challenges and Management of Liver Cirrhosis: Pathophysiology of Renal Dysfunction in Cirrhosis. Digestive Diseases, 2015, 33, 534-538.	1.9	20
143	Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. Journal of Hepatology, 2015, 62, S131-S143.	3.7	358
144	Hepatorenal syndrome: The last pieces of the puzzle or not yet?. Hepatology, 2015, 62, 352-354.	7.3	2

#	ARTICLE	IF	CITATIONS
145	Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis: A case-control study. <i>Journal of Hepatology</i> , 2015, 63, 593-600.	3.7	53
146	Transient increase in urine protein excretion during treatment with terlipressin and albumin for type-1 hepatorenal syndrome. <i>Journal of Hepatology</i> , 2015, 62, 493-495.	3.7	1
147	Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis. <i>Gut</i> , 2015, 64, 1616-1622.	12.1	86
148	Hyponatremia influences the outcome of patients with acute-on-chronic liver failure: an analysis of the CANONIC study. <i>Critical Care</i> , 2014, 18, 700.	5.8	41
149	Type-1 hepatorenal syndrome associated with infections in cirrhosis: Natural history, outcome of kidney function, and survival. <i>Hepatology</i> , 2014, 59, 1505-1513.	7.3	68
150	Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). <i>Journal of Hepatology</i> , 2014, 60, 275-281.	3.7	259
151	Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. <i>Journal of Hepatology</i> , 2014, 60, 1310-1324.	3.7	685
152	Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. <i>Journal of Hepatology</i> , 2014, 60, 955-961.	3.7	100
153	CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. <i>Gut</i> , 2014, 63, 1782-1792.	12.1	118
154	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2014, 61, 1038-1047.	3.7	741
155	From Refractory Ascites to Dilutional Hyponatremia and Hepatorenal Syndrome: Current Options for Treatment. <i>Current Hepatology Reports</i> , 2014, 13, 189-197.	0.9	1
156	The biliary epithelium gives rise to liver progenitor cells. <i>Hepatology</i> , 2014, 60, 1367-1377.	7.3	158
157	A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis. <i>Gastroenterology</i> , 2014, 146, 1231-1239.e6.	1.3	353
158	Reply to: "To close the stable door before the horse has bolted". <i>Journal of Hepatology</i> , 2014, 60, 679-680.	3.7	0
159	Chronic kidney disease: A major concern in liver transplantation in the XXI century. <i>Journal of Hepatology</i> , 2014, 61, 196-197.	3.7	7
160	Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. <i>Journal of Hepatology</i> , 2014, 61, 35-42.	3.7	98
161	Toward an Improved Definition of Acute-on-Chronic Liver Failure. <i>Gastroenterology</i> , 2014, 147, 4-10.	1.3	255
162	Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development. <i>Metabolic Brain Disease</i> , 2013, 28, 301-305.	2.9	26

#	ARTICLE	IF	CITATIONS
163	Hyponatremia in Cirrhosis: Evaluation and Treatment. , 2013, , 145-157.		1
164	Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: A randomized double-blind study. Journal of Hepatology, 2013, 59, 1184-1192.	3.7	102
165	Relative adrenal insufficiency in decompensated cirrhosis: Relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death. Hepatology, 2013, 58, 1757-1765.	7.3	120
166	A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. Journal of Hepatology, 2013, 59, 474-481.	3.7	249
167	Current treatment strategies for hepatorenal syndrome. Clinical Liver Disease, 2013, 2, 136-139.	2.1	2
168	Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut, 2013, 62, 452-460.	12.1	167
169	Reply to: "Effect of albumin on survival in septic cirrhotic patients other than spontaneous bacterial peritonitis. The question remains open" Journal of Hepatology, 2013, 58, 640.	3.7	4
170	Reply to: "Acute-on-chronic liver failure " Its definition remains unclear" Journal of Hepatology, 2013, 59, 191.	3.7	2
171	Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. Gastroenterology, 2013, 144, 1426-1437.e9.	1.3	2,211
172	LEFT ventricular function assessed by echocardiography in cirrhosis: Relationship to systemic hemodynamics and renal dysfunction. Journal of Hepatology, 2013, 58, 51-57.	3.7	129
173	Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology, 2013, 58, 1836-1846.	7.3	327
174	Results of pretransplant treatment of hepatorenal syndrome with terlipressin. Current Opinion in Organ Transplantation, 2013, 18, 265-270.	1.6	10
175	Renal failure in cirrhosis: prerenal azotemia, hepatorenal syndrome and acute tubular necrosis. Nephrology Dialysis Transplantation, 2012, 27, 2625-2628.	0.7	37
176	Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut, 2012, 61, 108-116.	12.1	121
177	Management of critically-ill cirrhotic patients. Journal of Hepatology, 2012, 56, S13-S24.	3.7	113
178	Acute Kidney Injury Is an Early Predictor of Mortality for Patients With Alcoholic Hepatitis. Clinical Gastroenterology and Hepatology, 2012, 10, 65-71.e3.	4.4	155
179	Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology, 2012, 56, 571-578.	3.7	115
180	Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study. Journal of Hepatology, 2012, 56, 1040-1046.	3.7	50

#	ARTICLE	IF	CITATIONS
181	Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. <i>Journal of Hepatology</i> , 2012, 57, 267-273.	3.7	191
182	Reply to: "Encephalopathy or hepatic encephalopathy?" <i>Journal of Hepatology</i> , 2012, 57, 929-930.	3.7	0
183	Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. <i>Journal of Hepatology</i> , 2012, 57, 759-765.	3.7	179
184	Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice. <i>Journal of Hepatology</i> , 2012, 57, 1135-1140.	3.7	87
185	Effects of Fractionated Plasma Separation and Adsorption on Survival in Patients With Acute-on-Chronic Liver Failure. <i>Gastroenterology</i> , 2012, 142, 782-789.e3.	1.3	355
186	Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites. <i>Digestive and Liver Disease</i> , 2012, 44, 239-244.	0.9	17
187	Factors related to quality of life in patients with cirrhosis and ascites: Relevance of serum sodium concentration and leg edema. <i>Journal of Hepatology</i> , 2012, 57, 1199-1206.	3.7	116
188	Acute-on chronic liver failure. <i>Journal of Hepatology</i> , 2012, 57, 1336-1348.	3.7	545
189	Hepatic hemodynamics and transient elastography in alcoholic foamy degeneration: report of 2 cases. <i>Annals of Hepatology</i> , 2012, 11, 399-403.	1.5	10
190	Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study. <i>Hepatology</i> , 2012, 55, 1551-1561.	7.3	498
191	Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. <i>Hepatology</i> , 2012, 55, 1931-1941.	7.3	177
192	Hepatorenal Syndrome: A Severe, but Treatable, Cause of Kidney Failure in Cirrhosis. <i>American Journal of Kidney Diseases</i> , 2012, 59, 874-885.	1.9	58
193	Terlipressin for Hepatorenal Syndrome: Predictors of Response. <i>Frontiers of Gastrointestinal Research</i> , 2011, , 172-177.	0.1	1
194	Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis. <i>Gastroenterology</i> , 2011, 140, 488-496.e4.	1.3	311
195	Management of patients with cirrhosis awaiting liver transplantation. <i>Cut</i> , 2011, 60, 412-421.	12.1	64
196	The Amount of Alcohol Consumption Negatively Impacts Short-Term Mortality in Mexican Patients With Alcoholic Hepatitis. <i>American Journal of Gastroenterology</i> , 2011, 106, 1472-1480.	0.4	33
197	Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy. <i>Journal of Hepatology</i> , 2011, 55, 564-573.	3.7	96
198	Pharmacological management of hepatorenal syndrome: Lessons from non-responders. <i>Journal of Hepatology</i> , 2011, 55, 268-269.	3.7	17

#	ARTICLE	IF	CITATIONS
199	Acute-on-chronic liver failure: the kidneys. <i>Current Opinion in Critical Care</i> , 2011, 17, 184-189.	3.2	38
200	Hepatorenal syndrome, pharmacological therapy, and liver transplantation. <i>Liver Transplantation</i> , 2011, 17, 1244-1246.	2.4	11
201	Renal Dysfunction and Pathogenesis and Treatment of Ascites and Hepatorenal Syndrome in Cirrhosis. , 2011, , 102-112.		1
202	Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. <i>Hepatology</i> , 2010, 51, 219-226.	7.3	211
203	Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. <i>Hepatology</i> , 2010, 51, NA-NA.	7.3	96
204	Chrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. <i>Hepatology</i> , 2010, 51, 974-985.	7.3	141
205	Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. <i>Hepatology</i> , 2010, 51, 1567-1576.	7.3	117
206	Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. <i>Hepatology</i> , 2010, 52, 1783-1790.	7.3	88
207	Hepatocarcinoma cells stimulate the growth, migration and expression of pro-angiogenic genes in human hepatic stellate cells. <i>Liver International</i> , 2010, 30, 31-41.	3.9	44
208	Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. <i>Liver International</i> , 2010, 30, 1137-1142.	3.9	87
209	Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. <i>Journal of Hepatology</i> , 2010, 53, 283-290.	3.7	78
210	Renal and circulatory dysfunction in cirrhosis: Current management and future perspectives. <i>Journal of Hepatology</i> , 2010, 53, 1135-1145.	3.7	97
211	Diuretic agents for ascites: joining forces from the start?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 310-311.	17.8	1
212	Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, G726-G734.	3.4	110
213	Clinically relevant differences in the model for end-stage liver disease and model for end-stage liver disease-sodium scores determined at three university-based laboratories of the same area. <i>Liver Transplantation</i> , 2009, 15, 300-305.	2.4	18
214	Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. <i>Liver Transplantation</i> , 2009, 15, S1-S34.	2.4	135
215	Is albumin infusion necessary after large volume paracentesis? Pro & main arguments. <i>Liver International</i> , 2009, 29, 636-638.	3.9	23
216	Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2009, 41, e4-e7.	0.9	14

#	ARTICLE	IF	CITATIONS
217	Hepatic Expression of CXC Chemokines Predicts Portal Hypertension and Survival in Patients With Alcoholic Hepatitis. <i>Gastroenterology</i> , 2009, 136, 1639-1650.	1.3	197
218	Hyponatremia Is a Risk Factor of Hepatic Encephalopathy in Patients With Cirrhosis: A Prospective Study With Time-Dependent Analysis. <i>American Journal of Gastroenterology</i> , 2009, 104, 1382-1389.	0.4	206
219	Renal Failure in Cirrhosis. <i>New England Journal of Medicine</i> , 2009, 361, 1279-1290.	27.0	713
220	Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G147-G156.	3.4	79
221	A Patient With Cirrhosis and Increasing Creatinine Level: What Is It and What to Do?. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1287-1291.	4.4	3
222	Portal hypertension. <i>Current Opinion in Gastroenterology</i> , 2009, 25, 195-201.	2.3	34
223	What's new in the treatment of ascites and spontaneous bacterial peritonitis. <i>Current Gastroenterology Reports</i> , 2008, 10, 7-14.	2.5	9
224	Effects of satavaptan, a selective vasopressin V ₂ receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial. <i>Hepatology</i> , 2008, 48, 204-213.	7.3	183
225	Hyponatremia in cirrhosis: Pathogenesis, clinical significance, and management. <i>Hepatology</i> , 2008, 48, 1002-1010.	7.3	267
226	Terlipressin and Albumin vs Albumin in Patients With Cirrhosis and Hepatorenal Syndrome: A Randomized Study. <i>Gastroenterology</i> , 2008, 134, 1352-1359.	1.3	541
227	Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. <i>Postgraduate Medical Journal</i> , 2008, 84, 662-670.	1.8	504
228	A New Scoring System for Prognostic Stratification of Patients With Alcoholic Hepatitis. <i>American Journal of Gastroenterology</i> , 2008, 103, 2747-2756.	0.4	268
229	Predicting Mortality in Cirrhosis – Serum Sodium Helps. <i>New England Journal of Medicine</i> , 2008, 359, 1060-1062.	27.0	39
230	The Management of Ascites and Hyponatremia in Cirrhosis. <i>Seminars in Liver Disease</i> , 2008, 28, 043-058.	3.6	79
231	Pathogenesis and Treatment of Hepatorenal Syndrome. <i>Seminars in Liver Disease</i> , 2008, 28, 081-095.	3.6	171
232	Complications of Cirrhosis. <i>Seminars in Liver Disease</i> , 2008, 28, 001-001.	3.6	2
233	MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. <i>Gut</i> , 2007, 56, 1283-1290.	12.1	180
234	Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. <i>Journal of Hepatology</i> , 2007, 46, 935-946.	3.7	135

#	ARTICLE	IF	CITATIONS
235	Vaptans: A promising therapy in the management of advanced cirrhosis. <i>Journal of Hepatology</i> , 2007, 46, 1150-1152.	3.7	26
236	Hepatic Expression of Candidate Genes in Patients With Alcoholic Hepatitis: Correlation With Disease Severity. <i>Gastroenterology</i> , 2007, 132, 687-697.	1.3	108
237	Primary Prophylaxis of Spontaneous Bacterial Peritonitis Delays Hepatorenal Syndrome and Improves Survival in Cirrhosis. <i>Gastroenterology</i> , 2007, 133, 818-824.	1.3	639
238	Bradykinin Attenuates Hepatocellular Damage and Fibrosis in Rats With Chronic Liver Injury. <i>Gastroenterology</i> , 2007, 133, 2019-2028.	1.3	41
239	Therapy with vasoconstrictor drugs in cirrhosis: The time has arrived. <i>Hepatology</i> , 2007, 46, 1685-1687.	7.3	12
240	Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in non-transplanted patients with chronic hepatitis C. <i>Liver Transplantation</i> , 2007, 13, 1017-1027.	2.4	24
241	Liver Transplant Using Donors After Unexpected Cardiac Death: Novel Preservation Protocol and Acceptance Criteria. <i>American Journal of Transplantation</i> , 2007, 7, 1849-1855.	4.7	279
242	Resistin as an Intrahepatic Cytokine. <i>American Journal of Pathology</i> , 2006, 169, 2042-2053.	3.8	142
243	Hepatorenal Syndrome. <i>Clinics in Liver Disease</i> , 2006, 10, 371-385.	2.1	16
244	Hyponatremia Impairs Early Posttransplantation Outcome in Patients With Cirrhosis Undergoing Liver Transplantation. <i>Gastroenterology</i> , 2006, 130, 1135-1143.	1.3	179
245	Hyponatremia in cirrhosis: clinical features and management. <i>Gastroenterologie Clinique Et Biologique</i> , 2006, 30, 1144-1151.	0.9	20
246	Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. <i>Hepatology</i> , 2006, 44, 1288-1295.	7.3	279
247	Hyponatremia in cirrhosis: Results of a patient population survey. <i>Hepatology</i> , 2006, 44, 1535-1542.	7.3	349
248	Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: Relationship with ascites and hepatorenal syndrome. <i>Hepatology</i> , 2006, 44, 1555-1563.	7.3	49
249	New Treatments of Hepatorenal Syndrome. <i>Seminars in Liver Disease</i> , 2006, 26, 254-264.	3.6	33
250	Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic stellate cells. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 291, G877-G884.	3.4	54
251	Therapy Insight: management of hepatorenal syndrome. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2006, 3, 338-348.	1.7	22
252	Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. <i>Hepatology</i> , 2005, 41, 579-587.	7.3	79

#	ARTICLE	IF	CITATIONS
253	MELD score and clinical type predict prognosis in hepatorenal syndrome: Relevance to liver transplantation. <i>Hepatology</i> , 2005, 41, 1282-1289.	7.3	338
254	Circulatory function and hepatorenal syndrome in cirrhosis. <i>Hepatology</i> , 2005, 42, 439-447.	7.3	537
255	Management of Refractory Ascites. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 1187-1191.	4.4	32
256	Management of complications of cirrhosis in patients awaiting liver transplantation. <i>Journal of Hepatology</i> , 2005, 42, S124-S133.	3.7	56
257	Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. <i>Journal of Hepatology</i> , 2005, 43, 317-323.	3.7	105
258	Genomic and functional characterization of stellate cells isolated from human cirrhotic livers. <i>Journal of Hepatology</i> , 2005, 43, 272-282.	3.7	78
259	Renal Failure in Patients With Cirrhosis and Sepsis Unrelated to Spontaneous Bacterial Peritonitis: Value of MELD Score. <i>Gastroenterology</i> , 2005, 129, 1944-1953.	1.3	232
260	Liver Fibrogenesis: A New Role for the Renin-Angiotensin System. <i>Antioxidants and Redox Signaling</i> , 2005, 7, 1346-1355.	5.4	141
261	Mechanisms of Sodium Retention, Ascites Formation, and Renal Dysfunction in Cirrhosis. , 2005, , 65-84.		3
262	Increased vascular heme oxygenase-1 expression contributes to arterial vasodilation in experimental cirrhosis in rats. <i>Hepatology</i> , 2004, 39, 1075-1087.	7.3	62
263	Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. <i>Hepatology</i> , 2004, 39, 1613-1622.	7.3	87
264	Management of hepatorenal syndrome: Another piece of the puzzle. <i>Hepatology</i> , 2004, 40, 16-18.	7.3	19
265	Effects of contrast media on renal function in patients with cirrhosis: A prospective study. <i>Hepatology</i> , 2004, 40, 646-651.	7.3	61
266	Contrast medium-associated renal dysfunction in patients with cirrhosis. <i>Hepatology</i> , 2004, 40, 1474-1474.	7.3	3
267	Management of Cirrhosis and Ascites. <i>New England Journal of Medicine</i> , 2004, 350, 1646-1654.	27.0	721
268	Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. <i>Journal of Hepatology</i> , 2004, 40, 140-146.	3.7	203
269	Goodbye from Barcelona!. <i>Journal of Hepatology</i> , 2004, 41, 893-895.	3.7	1
270	Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. <i>Hepatology</i> , 2003, 38, 452-459.	7.3	73

#	ARTICLE	IF	CITATIONS
271	The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. <i>Hepatology</i> , 2003, 38, 258-266.	7.3	744
272	Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. <i>Hepatology</i> , 2003, 38, 919-929.	7.3	186
273	Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. <i>Gastroenterology</i> , 2003, 125, 117-125.	1.3	317
274	Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: A randomized double-blind multicenter trial. <i>Gastroenterology</i> , 2003, 124, 933-939.	1.3	280
275	Hepatorenal syndrome. <i>Lancet</i> , The, 2003, 362, 1819-1827.	13.7	543
276	Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. <i>Hepatology</i> , 2003, 38, 919-929.	7.3	88
277	External validation of a prognostic model for predicting survival of cirrhotic patients with refractory ascites. <i>American Journal of Gastroenterology</i> , 2002, 97, 2374-2378.	0.4	27
278	Increased plasma levels of neuropeptide Y in hepatorenal syndrome. <i>Journal of Hepatology</i> , 2002, 36, 349-355.	3.7	23
279	Hepatorenal syndrome in cirrhosis: Pathogenesis and treatment. <i>Gastroenterology</i> , 2002, 122, 1658-1676.	1.3	143
280	Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. <i>Gastroenterology</i> , 2002, 123, 1839-1847.	1.3	523
281	Good news for hepatorenal syndrome. <i>Hepatology</i> , 2002, 36, 504-506.	7.3	18
282	Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. <i>Hepatology</i> , 2002, 36, 941-948.	7.3	497
283	A prognostic model for predicting survival in cirrhosis with ascites. <i>Journal of Hepatology</i> , 2001, 34, 46-52.	3.7	225
284	Human hepatic stellate cells secrete adrenomedullin: potential autocrine factor in the regulation of cell contractility. <i>Journal of Hepatology</i> , 2001, 34, 222-229.	3.7	24
285	Human myofibroblastic hepatic stellate cells express Ca ²⁺ -activated K ⁺ channels that modulate the effects of endothelin-1 and nitric oxide. <i>Journal of Hepatology</i> , 2001, 35, 739-748.	3.7	27
286	The model for end-stage liver disease (MELD) score predicts survival in patients with spontaneous bacterial peritonitis, and with ascites. <i>Gastroenterology</i> , 2001, 120, A378.	1.3	4
287	In vitro and in vivo activation of rat hepatic stellate cells results in de novo expression of L-type voltage-operated calcium channels. <i>Hepatology</i> , 2001, 33, 956-962.	7.3	57
288	Renal failure after upper gastrointestinal bleeding in cirrhosis: Incidence, clinical course, predictive factors, and short-term prognosis. <i>Hepatology</i> , 2001, 34, 671-676.	7.3	273

#	ARTICLE	IF	CITATIONS
289	Stenosis of the suprahepatic inferior vena cava as a complication of transjugular intrahepatic portosystemic shunt in Budd-Chiari patients. Liver Transplantation, 2001, 7, 649-651.	2.4	16
290	Diagnosis and treatment of hepatorenal syndrome. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2000, 14, 945-957.	2.4	10
291	Hepatorenal syndrome. Liver Transplantation, 2000, 6, S63-S71.	2.4	31
292	HEPATORENAL SYNDROME. Clinics in Liver Disease, 2000, 4, 487-507.	2.1	21
293	Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology, 2000, 119, 794-805.	1.3	69
294	Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology, 2000, 118, 1149-1156.	1.3	459
295	Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. Journal of Hepatology, 2000, 33, 43-48.	3.7	381
296	Atrial natriuretic peptide antagonizes endothelin-induced calcium increase and cell contraction in cultured human hepatic stellate cells. Hepatology, 1999, 30, 501-509.	7.3	30
297	Ascites and liver test abnormalities during severe ovarian hyperstimulation syndrome. American Journal of Gastroenterology, 1999, 94, 994-999.	0.4	11
298	Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis. New England Journal of Medicine, 1999, 341, 403-409.	27.0	1,519
299	Hepatorenal Syndrome. Journal of the American Society of Nephrology: JASN, 1999, 10, 1833-1839.	6.1	58
300	Increased renal and vascular cytosolic phospholipase A2 activity in rats with cirrhosis and ascites. Hepatology, 1998, 27, 42-47.	7.3	17
301	Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology, 1998, 27, 35-41.	7.3	296
302	Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology, 1998, 28, 39-44.	7.3	138
303	Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems. Hepatology, 1998, 28, 416-422.	7.3	374
304	Hyponatremia in cirrhosis: From pathogenesis to treatment. Hepatology, 1998, 28, 851-864.	7.3	237
305	Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites. Gastroenterology, 1998, 115, 147-156.	1.3	63
306	Increased adrenomedullin levels in cirrhosis: Relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology, 1998, 114, 336-343.	1.3	103

#	ARTICLE	IF	CITATIONS
307	Contraction of human hepatic stellate cells activated in culture: A role for voltage-operated calcium channels. <i>Journal of Hepatology</i> , 1998, 29, 398-408.	3.7	54
308	Antibiotic prophylaxis for spontaneous bacterial peritonitis: how and whom?. <i>Journal of Hepatology</i> , 1998, 29, 490-494.	3.7	31
309	Nitric Oxide as a Mediator of Hemodynamic Abnormalities and Sodium and Water Retention in Cirrhosis. <i>New England Journal of Medicine</i> , 1998, 339, 533-541.	27.0	396
310	Pathophysiology of Renal Dysfunction in Cirrhosis. <i>Digestion</i> , 1998, 59, 11-15.	2.3	9
311	Hepatorenal Syndrome. <i>Seminars in Liver Disease</i> , 1997, 17, 233-247.	3.6	83
312	Pathogenesis of Ascites in Cirrhosis. <i>Seminars in Liver Disease</i> , 1997, 17, 175-189.	3.6	104
313	PATHOPHYSIOLOGY, COMPLICATIONS, AND TREATMENT OF ASCITES. <i>Clinics in Liver Disease</i> , 1997, 1, 129-155.	2.1	21
314	Practical Recommendations for the Treatment of Ascites and Its Complications. <i>Drugs</i> , 1997, 54, 571-580.	10.9	21
315	Effect of therapeutic paracentesis on plasma volume and transvascular escape rate of albumin in patients with cirrhosis. <i>Journal of Hepatology</i> , 1997, 27, 645-653.	3.7	59
316	Urinary endothelin-like immunoreactivity in patients with cirrhosis. <i>Journal of Hepatology</i> , 1997, 27, 810-816.	3.7	15
317	Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trials of spironolactone versus placebo. <i>Journal of Hepatology</i> , 1997, 26, 614-620.	3.7	84
318	Management of ascites in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, 723-733.	2.8	8
319	10 Ascites and renal functional abnormalities in cirrhosis. Pathogenesis and treatment. <i>Bailliere's Clinical Gastroenterology</i> , 1997, 11, 365-385.	0.9	18
320	TIPS and refractory ascites. Lessons from the recent history of ascites therapy. <i>Journal of Hepatology</i> , 1996, 25, 221-223.	3.7	21
321	Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis. <i>Journal of Hepatology</i> , 1996, 24, 506-512.	3.7	35
322	Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. <i>Journal of Hepatology</i> , 1996, 25, 916-923.	3.7	57
323	Management of ascites, hepatorenal syndrome, and spontaneous bacterial peritonitis in cirrhosis. <i>Current Opinion in Gastroenterology</i> , 1995, 11, 233-237.	2.3	1
324	Treatment of patients with cirrhosis and refractory ascites using LeVeen shunt with titanium tip: Comparison with therapeutic paracentesis. <i>Hepatology</i> , 1995, 22, 124-131.	7.3	62

#	ARTICLE	IF	CITATIONS
325	Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone, and norepinephrine levels. <i>Hepatology</i> , 1995, 22, 479-487.	7.3	41
326	Endothelium-dependent vascular hyporesponsiveness without detection of nitric oxide synthase induction in aortas of cirrhotic rats. <i>Hepatology</i> , 1995, 22, 1856-1862.	7.3	60
327	Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. <i>Gastroenterology</i> , 1995, 109, 1624-1630.	1.3	165
328	Increased plasma endothelin in cirrhosis. Relationship with systemic endotoxemia and response to changes in effective blood volume. <i>Journal of Hepatology</i> , 1995, 22, 389-398.	3.7	49
329	Treatment of patients with cirrhosis and refractory ascites using LeVeen shunt with titanium tip: Comparison with therapeutic paracentesis*1. <i>Hepatology</i> , 1995, 22, 124-131.	7.3	54
330	Increased aortic cyclic guanosine monophosphate concentration in experimental cirrhosis in rats: Evidence for a role of nitric oxide in the pathogenesis of arterial vasodilation in cirrhosis*1. <i>Hepatology</i> , 1995, 21, 1625-1631.	7.3	9
331	Peripheral Arterial Vasodilation: Determinant of Functional Spectrum of Cirrhosis. <i>Seminars in Liver Disease</i> , 1994, 14, 14-22.	3.6	94
332	Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. <i>Hepatology</i> , 1994, 19, 1095-1099.	7.3	111
333	Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: A retrospective study. <i>Hepatology</i> , 1994, 20, 584-591.	7.3	43
334	Diagnosis of functional kidney failure of cirrhosis with Doppler sonography: Prognostic value of resistive index. <i>Hepatology</i> , 1994, 20, 839-844.	7.3	124
335	Total paracentesis with dextran 40 vs diuretics in the treatment of ascites in cirrhosis: a randomized controlled study. <i>Journal of Hepatology</i> , 1994, 20, 282-288.	3.7	80
336	Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: A retrospective study. <i>Hepatology</i> , 1994, 20, 584-591.	7.3	6
337	Effect of Dipyridamole on Kidney Function in Cirrhosis. <i>Hepatology</i> , 1993, 17, 59-64.	7.3	33
338	Spontaneous bacterial peritonitis in cirrhosis: Predictive factors of infection resolution and survival in patients treated with cefotaxime. <i>Hepatology</i> , 1993, 17, 251-257.	7.3	215
339	Brachial and femoral artery blood flow in cirrhosis: Relationship to kidney dysfunction. <i>Hepatology</i> , 1993, 17, 788-793.	7.3	136
340	Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. <i>Hepatology</i> , 1993, 17, 800-806.	7.3	63
341	Mechanism of sodium retention and ascites formation in cirrhosis. <i>Journal of Hepatology</i> , 1993, 17, S24-S28.	3.7	33
342	Paracentesis in the management of cirrhotic ascites. <i>Journal of Hepatology</i> , 1993, 17, S14-S18.	3.7	28

#	ARTICLE	IF	CITATIONS
343	Circulating levels of endothelin in cirrhosis. <i>Gastroenterology</i> , 1993, 104, 1485-1491.	1.3	198
344	Precision in nutritional diagnoses. <i>Gastroenterology</i> , 1993, 105, 1923.	1.3	1
345	Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. <i>Gastroenterology</i> , 1993, 105, 229-236.	1.3	820
346	Spontaneous bacterial peritonitis in cirrhosis: Predictive factors of infection resolution and survival in patients treated with cefotaxime. <i>Hepatology</i> , 1993, 17, 251-257.	7.3	15
347	Arteriolar vasodilation and the pathogenesis of the hyperdynamic circulation and renal sodium and water retention in cirrhosis. <i>Gastroenterology</i> , 1992, 102, 1077-1079.	1.3	37
348	Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. <i>Gastroenterology</i> , 1992, 102, 280-286.	1.3	44
349	Effects of somatostatin on renal function in cirrhosis. <i>Gastroenterology</i> , 1992, 103, 1868-1874.	1.3	54
350	Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. <i>Gastroenterology</i> , 1992, 102, 2114-2119.	1.3	59
351	Pharmacotherapy of Ascites Associated with Cirrhosis. <i>Drugs</i> , 1992, 43, 316-332.	10.9	36
352	Assessment of the renin-angiotensin system in cirrhotic patients. <i>Journal of Hepatology</i> , 1992, 15, 179-183.	3.7	59
353	Selective intestinal decontamination in the prevention of bacterial infection in patients with acute liver failure. <i>Journal of Hepatology</i> , 1992, 14, 280-285.	3.7	63
354	Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: Relevance of ascitic fluid protein concentration. <i>Hepatology</i> , 1992, 16, 724-727.	7.3	204
355	TREATMENT OF ASCITES IN CIRRHOSIS. <i>Gastroenterology Clinics of North America</i> , 1992, 21, 237-256.	2.2	36
356	Molecular forms and biological activity of atrial natriuretic factor in patients with cirrhosis and ascites. <i>Hepatology</i> , 1991, 14, 601-607.	7.3	17
357	Paracentesis with Intravenous Infusion of Albumin as Compared with Peritoneovenous Shunting in Cirrhosis with Refractory Ascites. <i>New England Journal of Medicine</i> , 1991, 325, 829-835.	27.0	294
358	Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. <i>Gastroenterology</i> , 1990, 98, 146-151.	1.3	208
359	Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. <i>Gastroenterology</i> , 1990, 99, 1736-1744.	1.3	179
360	Effects of intravenous amino acid infusion and dietary proteins on kidney function in cirrhosis. <i>Hepatology</i> , 1990, 11, 379-386.	7.3	19

#	ARTICLE	IF	CITATIONS
361	Natriuretic hormone activity in the urine of cirrhotic patients. Hepatology, 1990, 12, 467-475.	7.3	19
362	Norflaxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial. Hepatology, 1990, 12, 716-724.	7.3	587
363	Prognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients. Hepatology, 1990, 12, 753-760.	7.3	229
364	Prostaglandins and the treatment of hepatorenal syndrome in cirrhosis. Journal of Hepatology, 1990, 11, 142-144.	3.7	14
365	Natural history of hepatocellular carcinoma in Spain. Journal of Hepatology, 1990, 10, 311-317.	3.7	122
366	Treatment of ascites and renal failure in cirrhosis. Bailliere's Clinical Gastroenterology, 1989, 3, 165-186.	0.9	5
367	Recurrence of spontaneous bacterial peritonitis in cirrhosis: Frequency and predictive factors. Hepatology, 1988, 8, 27-31.	7.3	383
368	Atrial natriuretic factor in cirrhosis with ascites: Plasma levels, cardiac release and splanchnic extraction. Hepatology, 1988, 8, 636-642.	7.3	170
369	Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology, 1988, 94, 482-487.	1.3	438
370	Prostaglandin precursor fatty acids in cirrhosis with ascites: Effect of linoleic acid infusion in functional renal failure. Clinical Science, 1988, 74, 613-619.	4.3	17
371	Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology, 1988, 94, 1493-1502.	1.3	599
372	Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Gastroenterology, 1987, 93, 234-241.	1.3	463
373	Compensated cirrhosis: Natural history and prognostic factors. Hepatology, 1987, 7, 122-128.	7.3	972
374	Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites: An overview with emphasis on pathogenesis. American Journal of Medicine, 1986, 81, 104-122.	1.5	132
375	Urinary excretion of 6-keto-prostaglandin F1 α , thromboxane B2 and prostaglandin E2 in cirrhosis with ascites. Journal of Hepatology, 1986, 3, 111-117.	3.7	105
376	Sulindac Reduces the Urinary Excretion of Prostaglandins and Impairs Renal Function in Cirrhosis with Ascites. Nephron, 1986, 42, 298-303.	1.8	66
377	Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology, 1985, 5, 457-462.	7.3	299
378	PARACENTESIS VERSUS DIURETICS IN THE TREATMENT OF CIRRHOTICS WITH TENSE ASCITES. Lancet, The, 1985, 325, 611-612.	13.7	102

#	ARTICLE	IF	CITATIONS
379	Ascites, Hepatorenal Syndrome, and Spontaneous Bacterial Peritonitis. , 0, , 487-503.		1
380	The Systemic Circulation in Cirrhosis. , 0, , 137-155.		16
381	Medical Treatment of Ascites in Cirrhosis. , 0, , 227-240.		6
382	Prognosis of Patients with Cirrhosis and Ascites. , 0, , 260-270.		36
383	Liver Transplantation for Patients with Cirrhosis and Ascites. , 0, , 271-285.		5
384	Hepatorenal Syndrome in Cirrhosis: Clinical Features, Diagnosis, and Management. , 0, , 341-359.		3
385	The Sympathetic Nervous System in Cirrhosis. , 0, , 54-72.		7
386	Atrial Natriuretic Peptide and Other Natriuretic Factors in Cirrhosis. , 0, , 73-83.		2
387	Nitric Oxide and Systemic and Renal Hemodynamic Disturbances in Cirrhosis. , 0, , 105-114.		1
388	Management of ascites and spontaneous bacterial peritonitis. , 0, , 194-209.		0
389	Extracellular Fluid Volume Homeostasis. , 0, , 1-14.		0
390	Management of Ascites and Spontaneous Bacterial Peritonitis. , 0, , 158-167.		0